Detailed Mechanism Funding and Narrative

Details for Mechanism ID: 12462
Country/Region: Nigeria
Year: 2010
Main Partner: Not Available
Main Partner Program: NA
Organizational Type: Unknown
Funding Agency: HHS/CDC
Total Funding: $0

These funds are to be used by the award recipients of the FY10 HHS/CDC RFA, with emphasis on local implementing partners, to facilitate increased acceptance and use of PMTCT services by building strong linkages between health care providers and community support networks strengthening these linkages will support the mobilization of pregnant women to utilize appropriate PMTCT services. Funds will also support the strengthening of linkages between facility based activities and other programs/community based activities. This will improve the follow-up of PMTCT clients (mother/infant pair) and increase the utilization of PMTCT services.

An estimated minimum of 75,000 women will receive PMTCT services, be tested and receive their test results with 3,450 HIV+ being placed on ARV prophylaxis. It is estimated that 150 local staff in about 30 service outlets will be trained in PMTCT program standards in at least 4 Nigerian states.

Funding for Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT): $0

The recipients will be responsible for continuing to provide PMTCT services in current clinical outlets and service delivery sites. Counseling and testing with the "opt out" and will be provided to all pregnant women presenting at antenatal services. HIV infected women will be counseled on risks of HIV transmission and goals of the PMTCT program. They will be encouraged to bring partners and other family members for counseling and testing. HIV infected women eligible for ART will be provided with ART following the National guidelines. All participating laboratories will either have the capability of clinical HIV assessment including CD4 determination to ascertain ART eligibility by national and international ART criteria or will refer women to such services at another HIV service outlet in the geographic area. HIV infected women ineligible for initiation of ART will be offered combination of zidovudine from 28 weeks and single dose nevirapine at onset of labor as per the national guidelines. Women presenting at labor will be offered rapid testing and if HIV infected provided with single dose nevirapine. All infants born to HIV infected women will be provided with single dose nevirapine at birth and zidovudine for 6 weeks. After delivery, mothers and infants will be followed to monitor the mother's health and determine HIV status of the baby. Infant diagnosis of HIV will be by referral to qualified PEPFAR laboratories performing PCR if not available at the site, and if found positive the baby will continue to be monitored for eligibility for ART and per medical indications, be provided with cotrimoxazole prophylaxis.

CONTRIBUTIONS TO OVERALL PROGRAM AREA: With 30 sites in 4 states, the above described activity is in line with the USG`s target of having 80% coverage for PMTCT across the country.

LINKS TO OTHER ACTIVITIES: This activity is also linked to HVOP (12969.08), HBHC (12970.08), HCT (12972.08), HKID (14087.08), HVTB (12971.08), HTXS (14089.08) and joint awards for these program areas are anticipated.

Prevention for positives counseling will be integrated within PMTCT care for HIV+ women

POPULATIONS BEING TARGETED: This activity targets pregnant women who will be offered HIV counseling and testing, HIV+ pregnant women who will be offered ARV prophylaxis and infant feeding counseling, and HIV+ infants who will be offered ARV prophylaxis and infant HIV diagnostic testing.

EMPHASIS AREAS: The PMTCT service has an emphasis on Human Resources and Local Organization Capacity Development.

COVERAGE AREAS: TBD when awarded.